SEC Comment Letter for Processa Pharmaceuticals, Inc. (PCSA) (CIK 0001533743) (PCSA) — Dec 18, 2019
Processa Pharmaceuticals, Inc. (PCSA) (CIK 0001533743)
Date: Dec. 18, 2019 · CIK: 0001533743 · Accession: 0000000000-19-016549
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-235511
Letter
December 17, 2019 David Young, Pharm.D, Ph.D. Chairman and Chief Executive Officer Processa Pharmaceuticals, Inc. 7380 Coca Cola Drive, Suite 106 Hanover, Maryland 21076 Re:Processa Pharmaceuticals, Inc. Registration Statement on Form S-1 Filed December 13, 2019 File No. 333-235511 Dear Dr. Young: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at (202) 551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Michael B. Kirwan, Esq.
Show Raw Text
December 17, 2019
David Young, Pharm.D, Ph.D.
Chairman and Chief Executive Officer
Processa Pharmaceuticals, Inc.
7380 Coca Cola Drive, Suite 106
Hanover, Maryland 21076
Re:Processa Pharmaceuticals, Inc.
Registration Statement on Form S-1
Filed December 13, 2019
File No. 333-235511
Dear Dr. Young:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tim Buchmiller at (202) 551-3635 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Michael B. Kirwan, Esq.